| Literature DB >> 27320912 |
Yubin Wang1, Joshua Hersheson2, Dulce Lopez1, Monia Hammer3, Yan Liu1, Ka-Hung Lee1, Vanessa Pinto4, Jeff Seinfeld1, Sarah Wiethoff5, Jiandong Sun4, Rim Amouri6, Faycal Hentati6, Neema Baudry1, Jennifer Tran1, Andrew B Singleton7, Marie Coutelier8, Alexis Brice9, Giovanni Stevanin10, Alexandra Durr9, Xiaoning Bi4, Henry Houlden11, Michel Baudry12.
Abstract
A CAPN1 missense mutation in Parson Russell Terrier dogs is associated with spinocerebellar ataxia. We now report that homozygous or heterozygous CAPN1-null mutations in humans result in cerebellar ataxia and limb spasticity in four independent pedigrees. Calpain-1 knockout (KO) mice also exhibit a mild form of ataxia due to abnormal cerebellar development, including enhanced neuronal apoptosis, decreased number of cerebellar granule cells, and altered synaptic transmission. Enhanced apoptosis is due to absence of calpain-1-mediated cleavage of PH domain and leucine-rich repeat protein phosphatase 1 (PHLPP1), which results in inhibition of the Akt pro-survival pathway in developing granule cells. Injection of neonatal mice with the indirect Akt activator, bisperoxovanadium, or crossing calpain-1 KO mice with PHLPP1 KO mice prevented increased postnatal cerebellar granule cell apoptosis and restored granule cell density and motor coordination in adult mice. Thus, mutations in CAPN1 are an additional cause of ataxia in mammals, including humans.Entities:
Keywords: apoptosis; ataxia; calpain-1; cerebellum; development
Mesh:
Substances:
Year: 2016 PMID: 27320912 PMCID: PMC4927383 DOI: 10.1016/j.celrep.2016.05.044
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423